Abstract
22-oxacalcitriol (OCT) is a vitamin D3 analog and a vitamin D receptor activator (VDRA) that is used as a drug for secondary hyperparathyroidism (SHPT) and has been available clinically in Japan since 2000. The pharmacological characteristics of OCT include rapid clearance from the systemic circulation compared to that of calcitriol, good tissue distribution, and relatively long retention in the nucleus in parathyroid cells. In clinical studies, OCT has been shown to decrease the parathyroid hormone (PTH) level with an effect equivalent to that of calcitriol. Other reports show that OCT produces superior improvement of bone metabolism compared to calcitriol. Treatment with ultrasound-guided direct injection of OCT into the parathyroid has also been attempted. In animal studies, OCT does not influence the blood Ca or P level and is less likely to promote progression of calcification in cardiovascular tissue. The influence of VDRAs including OCT on the progression of cardiovascular lesions and survival in SHPT patients requires further studies.
Keywords: Maxacalcitriol, percutaneous VDRA injection therapy, secondary hyperparathyroidism, vitamin D analogs, vitamin D receptor activator, 22-oxacalcitriol.
Current Vascular Pharmacology
Title:Clinical Uses of 22-Oxacalcitriol
Volume: 12 Issue: 2
Author(s): Masahide Mizobuchi and Hiroaki Ogata
Affiliation:
Keywords: Maxacalcitriol, percutaneous VDRA injection therapy, secondary hyperparathyroidism, vitamin D analogs, vitamin D receptor activator, 22-oxacalcitriol.
Abstract: 22-oxacalcitriol (OCT) is a vitamin D3 analog and a vitamin D receptor activator (VDRA) that is used as a drug for secondary hyperparathyroidism (SHPT) and has been available clinically in Japan since 2000. The pharmacological characteristics of OCT include rapid clearance from the systemic circulation compared to that of calcitriol, good tissue distribution, and relatively long retention in the nucleus in parathyroid cells. In clinical studies, OCT has been shown to decrease the parathyroid hormone (PTH) level with an effect equivalent to that of calcitriol. Other reports show that OCT produces superior improvement of bone metabolism compared to calcitriol. Treatment with ultrasound-guided direct injection of OCT into the parathyroid has also been attempted. In animal studies, OCT does not influence the blood Ca or P level and is less likely to promote progression of calcification in cardiovascular tissue. The influence of VDRAs including OCT on the progression of cardiovascular lesions and survival in SHPT patients requires further studies.
Export Options
About this article
Cite this article as:
Mizobuchi Masahide and Ogata Hiroaki, Clinical Uses of 22-Oxacalcitriol, Current Vascular Pharmacology 2014; 12 (2) . https://dx.doi.org/10.2174/15701611113119990023
DOI https://dx.doi.org/10.2174/15701611113119990023 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nuclear Imaging of Hormonal Receptor Status in Breast Cancer: A Tool for Guiding Endocrine Treatment and Drug Development
Current Cancer Drug Targets Statin Treatment and Carotid Plaque Composition: A Review of Clinical Studies
Current Vascular Pharmacology Monocyte Adhesion in Atherosclerosis: A Biomechanical Approach
Vascular Disease Prevention (Discontinued) Next Steps in Alzheimers Disease Research: Interaction between Epidemiology and Basic Science
Current Alzheimer Research Natural Polymeric Nanoparticles for Brain-Targeting: Implications on Drug and Gene Delivery
Current Pharmaceutical Design Crucial Protein Based Drug Targets and Potential Inhibitors for Osteoporosis: New Hope and Possibilities
Current Drug Targets Merging Traditional Chinese Medicine with Modern Drug Discovery Technologies to Find Novel Drugs and Functional Foods
Current Drug Discovery Technologies Cardiovascular Effects of Methotrexate in Rheumatoid Arthritis Revisited
Current Medicinal Chemistry Recent Patents in CNS Drug Discovery: The Management of Inflammation in the Central Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) Targeting Dyslipidemia in the Metabolic Syndrome: An Update
Current Vascular Pharmacology Fluctuations and Responses in Stochastic Motions of <i>Volvox</i> Colonies
Current Physical Chemistry Dendritic Cells in Atherosclerosis
Current Pharmaceutical Design Aortic Wave Velocity: A Noninvasive Method to Measure the Stiffness of Arteries and the Clinical Results of Supplements That Appear to Improve Arterial Stiffness
Current Aging Science Identifying Changes in the Synaptic Proteome of Cirrhotic Alcoholic Superior Frontal Gyrus
Current Neuropharmacology The Role of Functional Neuroimaging in Mild Cognitive Impairment
Current Medical Imaging Neuron-Specific Mitochondrial DNA Deletion Levels in Sporadic Alzheimer´s Disease
Current Alzheimer Research Immunosuppressive and Antiviral Treatment of Inflammatory Cardiomyopathy
Recent Patents on Cardiovascular Drug Discovery Drug Development Strategy for Type 2 Diabetes: Targeting Positive Energy Balances
Current Drug Targets Evaluation of Homocysteine, Vitamin B12 and Folic Acid Levels During all the Trimesters in Pregnant and Preeclamptic Womens
Current Hypertension Reviews Flavonoids and the Brain: Evidences and Putative Mechanisms for a Protective Capacity
Current Neuropharmacology